COSOPT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cosopt, and what generic alternatives are available?
Cosopt is a drug marketed by Thea Pharma and is included in two NDAs.
The generic ingredient in COSOPT is dorzolamide hydrochloride; timolol maleate. There are fifteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride; timolol maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cosopt
A generic version of COSOPT was approved as dorzolamide hydrochloride; timolol maleate by SANDOZ on November 6th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COSOPT?
- What are the global sales for COSOPT?
- What is Average Wholesale Price for COSOPT?
Summary for COSOPT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 35 |
| Patent Applications: | 385 |
| Drug Prices: | Drug price information for COSOPT |
| What excipients (inactive ingredients) are in COSOPT? | COSOPT excipients list |
| DailyMed Link: | COSOPT at DailyMed |
Recent Clinical Trials for COSOPT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wills Eye | Phase 2/Phase 3 |
| Mid Atlantic Retina | Phase 2/Phase 3 |
| Wills Eye | Phase 2 |
Pharmacology for COSOPT
| Drug Class | Carbonic Anhydrase Inhibitor beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists Carbonic Anhydrase Inhibitors |
Paragraph IV (Patent) Challenges for COSOPT
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| COSOPT | Ophthalmic Solution | dorzolamide hydrochloride; timolol maleate | 2%/0.5% | 020869 | 1 | 2005-10-11 |
US Patents and Regulatory Information for COSOPT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | AT1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Thea Pharma | COSOPT PF | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 202667-001 | Feb 1, 2012 | AT2 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COSOPT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COSOPT
See the table below for patents covering COSOPT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 648659 | ⤷ Sign Up | |
| Switzerland | 0509752 | ⤷ Sign Up | |
| New Zealand | 225166 | SUBSTITUTED AROMATIC SULPHONAMIDE DERIVATIVES AND OPHTHALMOLOGICAL FORMULATIONS | ⤷ Sign Up |
| Greece | 3031467 | ⤷ Sign Up | |
| Denmark | 167874 | ⤷ Sign Up | |
| Canada | 1328262 | SULFONAMIDES AROMATIQUES SUBSTITUES EN TANT QU'AGENTS ANTI-GLAUCOMATEUX (SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS) | ⤷ Sign Up |
| Japan | H0631247 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COSOPT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0509752 | SPC/GB99/043 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 |
| 0509752 | 49/1999 | Austria | ⤷ Sign Up | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
| 0509752 | CA 2000 00002 | Denmark | ⤷ Sign Up | |
| 0509752 | C990041 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
| 0296879 | 96C0003 | Belgium | ⤷ Sign Up | PRODUCT NAME: HYDROCHLORIDUM, EQ. DORZOLAMIDUM; NAT. REGISTRATION NO/DATE: 922 IS 168 F13 19951019; FIRST REGISTRATION: SE 12208 19941219 |
| 0509752 | 2000C/001 | Belgium | ⤷ Sign Up | PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
